• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Selcia, NeuroVice partner to generate mitochondrial compounds

Selcia, NeuroVice partner to generate mitochondrial compounds

September 20, 2011
CenterWatch Staff

Selcia, the UK-based contract research organization that recently extended its international reach with a facility in the US, has agreed to collaborate with Swedish drug development company NeuroVive Pharmaceutical on generating new compounds targeted at mitochondrial physiology and pathophysiology, according to PharmaTimes.

Mitochondria are the “energy-producing powerhouses” of human cells and are a critical component in optimizing cellular function and survival as well as initiating cell death, the new partners noted.

Mitochondrial dysfunction has been implicated in acute conditions such as stroke and heart failure, chronic diseases like diabetes, neurodegenerative conditions such as Alzheimer´s disease and in the ageing process.

Financial details of the collaboration were not disclosed. The two companies said they would jointly invest in the initiative, combining Selcia´s expertise in medicinal and analytical chemistry with NeuroVive´s advanced research and development programs in mitochondrial medicine.

According to Simon Saxby, chief executive officer of Selcia, the partners’ combined resources have the potential to “yield a number of new drugs and supplements that could revolutionize the treatment of diseases caused by mitochondrial dysfunction, as well as recovery regimens for a number of patient populations.”

NeuroVive’s primary focus is on drugs for the treatment of acute brain injury, reperfusion injury in myocardial infarction and other acute injuries where mitochondrial energy production is critical for clinical outcome.

The company’s R&D efforts center on developing new variants of cyclophilin-D-inhibiting cyclosporins and on studying ways of transporting these drugs across the blood-brain barrier to the central nervous system.

“This collaboration with Selcia will allow us to accelerate the discovery and development of new mitochondrial medicines and drug-like compounds within the scope of our current R&D budget in the discovery phase,” commented NeuroVive’s chief scientific officer, Eskil Elmér.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing